ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2235

Factors Associated with Opioid Use in End-Stage Knee, Hip and Spine Osteoarthritis

J. Denise Power1, Anthony V. Perruccio1, Rajiv Gandhi1, Christian Veillette1, J. Roderick Davey1, Stephen J. Lewis1, Khalid Syed1, Nizar Mahomed1 and Y. Raja Rampersaud2, 1Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 2Arthritis Program, Krembil Research Institute, University Health Network, Torotno, ON, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: opioids, osteoarthritis and pain management

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: ARHP Pain – Clinical Aspects Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The use of prescription opioids has been under increasing scrutiny due to concerns about the potential for misuse, dependency and increased adverse events. The objectives of our study were to examine the rates of prescription opioid use among pre-surgical knee, hip and spine osteoarthritis (OA) patients as well as the association between use and a range of socio-demographic and health status characteristics.

Methods: Study participants were 1204 patients with knee (N=577), hip (N=459) and spine (N=168) OA scheduled for surgery at a tertiary care hospital in Toronto, Canada. In pre-surgery questionnaires, data were collected on current usage (never, sometimes, daily) of opioid pain medications, as well as other prescription (NSAIDs, anti-depressants, neuroleptics) and over-the-counter pain medications for arthritis/joint pain. Additional questionnaire variables included: socio-demographics (age, sex, education), body mass index, comorbidity, depressive symptoms (Hospital Anxiety and Depression Scale) and pain level (0-10 numeric rating scale for average pain in the past week). Rates of opioid use were calculated by sex, age (<65 and 65+) and surgical site. Multivariable logistic regression was used to examine the associations between current reported opioid use (outcome: sometimes/daily vs. never) and other study variables.

Results: Participants were of mean age 65.6 years; 55.5% were women. Overall, 15% of patients reported ‘sometimes’ using opioid and an additional 15% reported ‘daily’ use. Any reported use of opioid was highest among spine OA patients (40%) and similar among knee and hip patients (28% and 30%). Younger women (<65 years) reported the greatest use of opioid overall, and particularly among spine patients (61%). From multivariable logistic regression, greater likelihood of opioid use was significantly associated with spine OA (vs. knee OA; p=0.03), younger age (p=0.02), obesity (vs. underweight/normal; p<0.01), fibromyalgia (present vs. absent; p=0.02), greater depressive symptoms (p=0.01), greater pain (p<0.001) and current use of other prescription pain medication (p<0.001).

Conclusion: Nearly a third of pre-surgical knee, hip and spine OA patients reported using prescription opioid medication for their OA pain. The higher use among younger individuals and those with greater depressive symptoms may warrant attention given growing concerns around adverse outcomes related to opioid use. While increased use of opioids among those with higher levels of current pain may be expected, this additionally raises questions as to whether these individuals are deriving intended clinical benefits. Further, available research suggests that opioid use in the surgical OA population may negatively impact outcomes. Consideration of pre-surgical opioid use screening, including potential dependency, may be warranted for patients undergoing surgery for OA.


Disclosure: J. D. Power, None; A. V. Perruccio, None; R. Gandhi, None; C. Veillette, None; J. R. Davey, None; S. J. Lewis, None; K. Syed, None; N. Mahomed, None; Y. R. Rampersaud, None.

To cite this abstract in AMA style:

Power JD, Perruccio AV, Gandhi R, Veillette C, Davey JR, Lewis SJ, Syed K, Mahomed N, Rampersaud YR. Factors Associated with Opioid Use in End-Stage Knee, Hip and Spine Osteoarthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/factors-associated-with-opioid-use-in-end-stage-knee-hip-and-spine-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-opioid-use-in-end-stage-knee-hip-and-spine-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology